Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer

被引:1
|
作者
Tang, Tao [1 ,2 ]
Zhi, Jingtai [3 ]
Zhang, Wei [1 ]
Hu, Linfei [1 ]
Ruan, Xianhui [1 ]
Chen, Xiaoyu [1 ]
Wang, Zhaohui [4 ]
Zheng, Xiangqian [1 ]
Gao, Ming [1 ,5 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Tumor, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China
[2] North Sichuan Med Coll, Inst Hepato Biliary Pancreat Intestinal Dis, Dept Hepatobiliary Surg 1, Affiliated Hosp, Nanchong, Peoples R China
[3] Tianjin First Cent Hosp, Dept Otolaryngol Head & Neck Surg, Tianjin, Peoples R China
[4] Univ Elect Sci & Technol China, Sch Med, Dept Head & Neck Surg, Sichuan Canc Hosp & Inst,Sichuan Canc Ctr, Chengdu, Peoples R China
[5] Tianjin Union Med Ctr, Dept Breast & Thyroid Surg, Tianjin, Peoples R China
关键词
PAPILLARY; SURVIVAL; ASSOCIATION; MANAGEMENT;
D O I
10.1155/2022/4348396
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose: The purpose of the current study was to determine whether older patients with differentiated thyroid cancer (DTC) who received surgical treatment had a better cause-specific survival (CSS) than patients who were recommended surgery, but declined, and whether patients who underwent postoperative RAI-131 therapy had an impact on CSS based on TNM staging and number of lymph node metastases for all total or near-total thyroidectomy patients. Patients and Methods: This retrospective, population-based study analyzed the clinical data of 162 DTC patients from signal institution in China and 26,487 cases from the Surveillance, Epidemiology, and End Results (SEER) program registry. The patients were divided into two groups (underwent surgery and surgery recommended, but not performed) in the SEER cohort. Furthermore, patients were grouped as follows: T4; N1b; M1; T1-3N0-1a; specific number of lymph node metastases; and total or near-total thyroidectomy. Results: The 120-month cause-specific survival (CSS) rate of women and men showed a gradual declining trend from 60-64 to >= 80years of age in the group that underwent surgery. The CSS rate of women and men showed a marked downward and irregular trend with an increase in age in the recommended, but no surgery group in the SEER cohort. Univariate analysis indicated that the surgery group had a higher 120-month CSS in women in most stages and men, compared with the no surgery group in the SEER cohort. The analysis of the SEER cohort showed that RAI-131 therapy was associated with an improved 80-month CSS in T4/N1b/M1 women (P<0.0183) and men (P<0.0011). However, there were no CSS differences between the RAI-131 therapy and the no-RAI-131 group for the patients with T4/N1b/M1 (AJCC 7th) thyroid cancer in the Chinese cohort. There was no CSS difference in women or men between the T1-3N0 and T1-3N1a patients in the SEER cohort. And similar findings were observed in T1-3N1a patients in the Chinese cohort. There was no statistical difference between the two subgroups. Conclusions: Surgical treatment should be recommended for elderly DTC patients because surgery can lead to a better CSS. High-risk patients achieve a higher benefit-to-risk ratio with RAI-131 therapy. To avoid the adverse effects associated with RAI-131 therapy, a multidisciplinary discussion should be arranged for intermediate- and low-risk patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies
    Nguyen, Nghi C.
    Anigati, Elena M.
    Desai, Neil B.
    Oz, Orhan K.
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (04) : 488 - 496
  • [42] Differentiated thyroid cancer in patients less than 20 years: Report of 20 cases
    Mhiri, A.
    Ghezaiel, M. Jemai
    Elbez, I.
    Slim, I.
    Yeddes, I.
    Meddeb, I.
    Ben Slimene, M. Faouzi
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2013, 37 (10-11): : 416 - 419
  • [43] Lymph node metastases >5 and metastatic lymph node ratio >0.30 of differentiated thyroid cancer predict response to radioactive iodine
    Yun, Canhua
    Xiao, Juan
    Cao, Jingjia
    Shao, Chunchun
    Wang, Lihua
    Zhang, Wei
    Jia, Hongying
    CANCER MEDICINE, 2021, 10 (21): : 7610 - 7619
  • [44] Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective
    Higashi, Tatsuya
    Kudo, Takashi
    Kinuya, Seigo
    ANNALS OF NUCLEAR MEDICINE, 2012, 26 (02) : 99 - 112
  • [45] Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer
    Boucher, Andree
    Ezzat, Shereen
    Hotte, Sebastien
    Rachinsky, Irina
    Rajaraman, Murali
    Ruether, Dean
    Wiseman, Sam M.
    Brierley, James
    Ho, Cheryl
    Krzyzanowska, Monika
    Lamond, Nathan
    Massicotte, Marie-Helene
    Joseph, Shereen
    Herscovitch, Kassey
    Sikora, Lindsey
    Winquist, Eric
    ORAL ONCOLOGY, 2021, 121
  • [46] The efficacy of adjuvant radioactive iodine after reoperation in patients with persistent or recurrent differentiated thyroid cancer: a systematic review
    Raghupathy, Jaivikash
    Tan, Benjamin Kye Jyn
    Song, Harris J. J. M. D.
    Chia, Alys Z. Q.
    Tan, Yi Zhao
    Yang, Samantha Peiling
    Parameswaran, Rajeev
    LANGENBECKS ARCHIVES OF SURGERY, 2023, 408 (01)
  • [47] Changes in the Pulmonary Function Test after Radioactive Iodine Treatment in Patients with Pulmonary Metastases of Differentiated Thyroid Cancer
    Jang, Eun Kyung
    Kim, Won Gu
    Kim, Ho-Cheol
    Huh, Jin-Won
    Kwon, Hyemi
    Choi, Yun Mi
    Jeon, Min Ji
    Kim, Tae Yong
    Shong, Young Kee
    Ryu, Jin-Sook
    Kim, Won Bae
    PLOS ONE, 2015, 10 (04):
  • [48] Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment
    Yi, Wook
    Kim, Bo Hyun
    Kim, Mijin
    Ryang, So Ree
    Jang, Min Hee
    Kim, Jeong Mi
    Kim, Eun Heui
    Jeon, Yun Kyung
    Kim, Sang Soo
    Kim, In Joo
    ENDOCRINE JOURNAL, 2020, 67 (12) : 1193 - 1198
  • [49] Association of the Cumulative Dose of Radioactive Iodine Therapy With Overall Survival in Patients With Differentiated Thyroid Cancer and Pulmonary Metastases
    Yang, Jing
    Zheng, Rong
    Liang, Meng
    Jia, Yingying
    Lin, Lin
    Gang, Jianhua
    Chen, Shengzu
    Li, Ye-Xiong
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [50] Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
    McFarland, Daniel C.
    Misiukiewicz, Krzysztof J.
    ONCOTARGETS AND THERAPY, 2014, 7 : 1291 - 1299